AgomAb Therapeutics N.V. (AGMB)
Health Care
AGMB is listed on Nasdaq, where its shares have traded since February 6, 2026. It represents shares of AgomAb Therapeutics N.V., which reports its financial results in EUR. SentiSense covers it in the Health Care sector.
About AgomAb Therapeutics N.V.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
Latest reported results
AgomAb Therapeutics N.V. reported revenue of 0.00 EUR for Q4 FY2025.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 34 institutions reported holding AGMB, with 26.0 million shares worth $337.0 million in aggregate. The largest reported holders were Eqt Fund Management S.a R.L, Sanofi and Redmile Group. Of the 5 largest reported holders, 1 added shares and 4 held their positions unchanged during the quarter.
More on AGMB
- AGMB sentiment: whether news and social coverage of AgomAb Therapeutics N.V. leans bullish or bearish, and the stories driving it.
- AGMB ownership: all 34 reporting institutions, plus insider and congressional trades.
- AGMB financials: revenue, net income, operating margin and free cash flow through Q4 FY2025.
SentiSense also tracks daily options readings for AgomAb Therapeutics N.V.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does AgomAb Therapeutics N.V. do?
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need.
What sector is AGMB in?
SentiSense classifies AgomAb Therapeutics N.V. in the Health Care sector.
Where does AGMB stock trade?
AGMB is listed on Nasdaq, where its shares have traded since February 6, 2026. It represents shares of AgomAb Therapeutics N.V., which reports its financial results in EUR.
Who is the CEO of AgomAb Therapeutics N.V.?
Tim Knotnerus is the chief executive officer of AgomAb Therapeutics N.V..